NASDAQ:ACRX
Delisted
AcelRx Pharmaceuticals Stock News
$0.86
+0 (+0%)
At Close: Apr 08, 2024
AcelRx Pharmaceuticals (NASDAQ:ACRX) Upgraded to Buy by Zacks Investment Research
02:18am, Sunday, 02'nd Aug 2020
Zacks Investment Research upgraded shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) from a sell rating to a buy rating in a research report released on Wednesday, Zacks.com reports. Zacks Investment Res
Earnings Preview: AcelRx Pharmaceuticals (ACRX) Q2 Earnings Expected to Decline
04:31pm, Monday, 27'th Jul 2020
AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Forecasts: Here's What Analysts Think The Future Holds For AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)
12:02pm, Saturday, 25'th Jul 2020
Celebrations may be in order for AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) shareholders, with the analysts delivering...
AcelRx Announces Exclusive Distribution and Promotion Partnership for DSUVIA®
12:40pm, Thursday, 23'rd Jul 2020
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced an agreement to market DSUVIA®, a sublingual opioid tablet in a single-dose applicator, within the den
AcelRx Announces $10 Million Common Stock Offering Priced At The Market
12:30pm, Thursday, 23'rd Jul 2020
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, to
Crédito privado: fundos terão que alongar prazos de resgate para entregar melhores retornos, dizem gestores
01:03am, Thursday, 16'th Jul 2020
Gestores da ARX, DLM Invista e SPX falaram sobre as perspectivas e as mudanças em curso na renda fixa, durante painel da Expert XP
AcelRx: Clever Solution To Painful Problem (NASDAQ:ACRX)
09:26pm, Friday, 26'th Jun 2020
AcelRx has two approved sufentanil-based pain relief therapies. AcelRx's Dsuvia started its launch in the slow lane. AcelRx's disintegrating Tetraphase arrangem
La Jolla Pharmaceutical Rekindles Interest In Tetraphase With Sweetened Offer
12:00am, Monday, 22'nd Jun 2020
The bidding war for Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) seems to be far from over.
What Happened: Tetraphase announced Monday that La Jolla Pharmaceutical Company...
Investors who take an interest in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) should definitely note that the...
ARC Resources (TSE:ARX) Downgraded by Scotiabank to Sector Perform
06:04am, Tuesday, 16'th Jun 2020
Scotiabank downgraded shares of ARC Resources (TSE:ARX) from an outperform rating to a sector perform rating in a research note published on Monday, BayStreet.CA reports. Scotiabank currently has C$7.
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) CEO Vincent J. Angotti Buys 7,547 Shares of Stock
06:04am, Tuesday, 16'th Jun 2020
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) CEO Vincent J. Angotti acquired 7,547 shares of the company’s stock in a transaction on Monday, June 15th. The stock was acquired at an average price of $1.3
Hummingbird Resources Is Giving Away 49% Of The Dugbe Gold Project For Peanuts (OTCMKTS:HUMRF)
05:17pm, Wednesday, 10'th Jun 2020
ARX to earn 49% in Dugbe by investing $10 million in exploration and delivering a DFS. The previous deal with a ARX foresaw the investment of $30 million in exp
The Daily Biotech Pulse: Keytruda Setback For Merck, Denali Pulls The Plug On Neurological Asset
11:30am, Wednesday, 10'th Jun 2020Edited Transcript of ACRX earnings conference call or presentation 16-Mar-20 12:30pm GMT
06:45pm, Monday, 08'th Jun 2020
Q4 2019 AcelRx Pharmaceuticals Inc Earnings Call
